Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

BACKGROUND: In the randomized, phase III, global SELECT-COMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which was maintained over 48 weeks. This post hoc ana...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Drugs Context
Main Authors: Pavelka, Karel, Szekanecz, Zoltán, Damjanov, Nemanja, Anić, Branimir, Tomšič, Matija, Mazurov, Vadim, Maksimovic, Marija, Nagy, Orsolya, Świerkot, Jerzy, Petranova, Tzvetanka, Veldi, Tiina, Baranauskaitė, Asta, Codreanu, Catalin, Andersone, Daina, Fleischmann, Roy
Formato: Artigo
Idioma:Inglês
Publicado em: BioExcel Publishing Ltd 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574850/
https://ncbi.nlm.nih.gov/pubmed/33123205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2020-7-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados